Repligen (NASDAQ:RGEN) Coverage Initiated at Roth Mkm

Investment analysts at Roth Mkm started coverage on shares of Repligen (NASDAQ:RGEN) in a research note issued on Friday,Benzinga reports. The firm set a “buy” rating and a $160.00 price target on the biotechnology company’s stock. Roth Mkm’s target price points to a potential upside of 21.94% from the company’s current price.

RGEN has been the topic of a number of other research reports. Barclays cut their price target on shares of Repligen from $175.00 to $145.00 and set an “overweight” rating on the stock in a report on Tuesday. HC Wainwright raised their target price on Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a research report on Wednesday, February 25th. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Finally, Wells Fargo & Company reduced their price objective on Repligen from $190.00 to $180.00 and set an “overweight” rating for the company in a research note on Wednesday, February 25th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Repligen currently has a consensus rating of “Moderate Buy” and a consensus target price of $172.36.

Repligen Stock Up 3.2%

RGEN stock opened at $131.21 on Friday. Repligen has a 12 month low of $109.66 and a 12 month high of $175.77. The firm has a market cap of $7.40 billion, a PE ratio of 154.36, a P/E/G ratio of 2.48 and a beta of 1.19. The firm has a 50 day simple moving average of $124.64 and a 200 day simple moving average of $146.39. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business had revenue of $197.91 million for the quarter, compared to analyst estimates of $192.23 million. During the same quarter in the previous year, the business earned $0.44 earnings per share. The firm’s revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities research analysts forecast that Repligen will post 1.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in RGEN. AQR Capital Management LLC acquired a new position in Repligen in the 1st quarter valued at approximately $262,000. Jones Financial Companies Lllp increased its stake in Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after buying an additional 6,238 shares during the period. Goldman Sachs Group Inc. increased its stake in Repligen by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after buying an additional 20,375 shares during the period. Bank of Nova Scotia increased its stake in Repligen by 88.0% in the 2nd quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock valued at $3,951,000 after buying an additional 14,860 shares during the period. Finally, Daiwa Securities Group Inc. increased its stake in Repligen by 29.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock valued at $3,880,000 after buying an additional 7,148 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.